FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffrey Weitz

Research Profile

Chemicals & Drugs

Physiology

Blood Coagulation

Anatomy

Thrombosis

Disorders

Phenomena

Protein Binding

Concepts & Ideas

Co-author Network

Publications

TOP 3
D Garcia; E Ramacciotti; Y C Barrett; Jeffrey I Weitz
Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.
Julia A Anderson; Wendy Lim; Jeffrey I Weitz
Genetics of coagulation: what the cardiologist needs to know.
Jeffrey I Weitz; Daniel J Quinlan; John W Eikelboom
Periprocedural management and approach to bleeding in patients taking dabigatran.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffrey Weitz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: D Garcia; E Ramacciotti; Y C Barrett; Jeffrey I Weitz
Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.
Journal of thrombosis and haemostasis : JTH 2013;11(2):245-52.
2013: Julia A Anderson; Wendy Lim; Jeffrey I Weitz
Genetics of coagulation: what the cardiologist needs to know.
The Canadian journal of cardiology 2013;29(1):75-88.
2012: Jeffrey I Weitz; Daniel J Quinlan; John W Eikelboom
Periprocedural management and approach to bleeding in patients taking dabigatran.
Circulation 2012;126(20):2428-32.
2012: Jonathan W Yau; John L Brash; James C Fredenburgh; Peng Liao; Robin Roberts; Alan R Stafford; Jeffrey I Weitz
Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo.
Acta biomaterialia 2012;8(11):4092-100.
2012: Howard H Chan; James C Fredenburgh; Beverly A Leslie; Robin S Roberts; Alan R Stafford; Nadine N Al-Aswad; Jeffrey I Weitz
By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin.
Biochemistry 2012;51(40):7964-73.
2012: Kyle A Arsenault; Brian Dale; Jeffrey S Ginsberg; Jack Hirsh; Jeremy S Paikin; Kevin Teoh; Jeffrey I Weitz; Richard P Whitlock; Ed Young; John W Eikelboom
Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial.
The Journal of thoracic and cardiovascular surgery 2012;144(4):944-950.e3.
2012: Calvin H Yeh; James C Fredenburgh; Jeffrey I Weitz
Oral direct factor Xa inhibitors.
Circulation research 2012;111(8):1069-78.
2012: Michiel Coppens; John W Eikelboom; David Gustafsson; Jeffrey I Weitz; Jack Hirsh
Translational success stories: development of direct thrombin inhibitors.
Circulation research 2012;111(7):920-9.
2012: John W Eikelboom; Jeffrey I Weitz
Anticoagulation therapy. Dabigatran and risk of myocardial infarction.
Nature reviews. Cardiology 2012;9(5):260-2.
2012: Jeffrey I Weitz
New oral anticoagulants: a view from the laboratory.
American journal of hematology 2012;87 Suppl 1():S133-6.
2012: James C Fredenburgh; C A Kretz; Jeffrey I Weitz
A Protease TAMER: a nucleic acid-based anticoagulant.
Journal of thrombosis and haemostasis : JTH 2012;10(5):867-9.
2012: Sara Alibeik; Jeffrey I Weitz; Jonathan W Yau; Shiping Zhu; John L Brash
Dual surface modification with PEG and corn trypsin inhibitor: effect of PEG:CTI ratio on protein resistance and anticoagulant properties.
Journal of biomedical materials research. Part A 2012;100(4):856-62.
2012: Paul Y Kim; Alan R Stafford; Long D Tieu; James C Fredenburgh; Jeffrey I Weitz
A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator.
The Journal of biological chemistry 2012;287(7):4652-61.
2012: John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest 2012;141(2 Suppl):e89S-119S.
2012: Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest 2012;141(2 Suppl):e120S-51S.
2012: John W Eikelboom; Jeffrey I Weitz
Idrabiotaparinux treatment for venous thromboembolism.
Lancet 2012;379(9811):96-8.
2011: Sara Alibeik; Jeffrey I Weitz; Jonathan W Yau; Shiping Zhu; John L Brash
Surface modification with polyethylene glycol-corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces.
Acta biomaterialia 2011;7(12):4177-86.
2011: Julia A M Anderson; Jeffrey I Weitz
Hypercoagulable states.
Critical care clinics 2011;27(4):933-52, vii.
2011: John W Eikelboom; Jeffrey I Weitz
Importance of family history as a risk factor for venous thromboembolism.
Circulation 2011;124(9):996-7.
2011: John W Eikelboom; Jeffrey I Weitz
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
BMJ (Clinical research ed.) 2011;342():c7270.
2011: Jeffrey I Weitz
Factor Xa and thrombin as targets for new oral anticoagulants.
Thrombosis research 2011;127 Suppl 2():S5-S12.
2010: Julia A M Anderson; Jeffrey I Weitz
Hypercoagulable states.
Clinics in chest medicine 2010;31(4):659-73.
2010: Jeffrey I Weitz; Charlie Cao; Bengt I Eriksson; William Fisher; Stuart Kupfer; Gary E Raskob; Jeffrey Spaeder; Alexander G G Turpie
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Thrombosis and haemostasis 2010;104(6):1150-7.
2010: Jeffrey I Weitz
Meeting the unmet needs in anticoagulant therapy.
European journal of haematology 2010;85 Suppl 72():p1-28.
2010: Jeffrey I Weitz
Meeting the unmet needs in anticoagulant therapy.
European journal of haematology. Supplementum 2010;(72):1-28.
2010: John W Eikelboom; Jeffrey I Weitz
New anticoagulants.
Circulation 2010;121(13):1523-32.
2010: Lori-Ann Linkins; Jeffrey I Weitz
New and emerging anticoagulant therapies for venous thromboembolism.
Current treatment options in cardiovascular medicine 2010;12(2):142-55.
2010: Jeffrey I Weitz
Potential of new anticoagulants in patients with cancer.
Thrombosis research 2010;125 Suppl 2():S30-5.
2010: Daniel S Weitz; Jeffrey I Weitz
Update on heparin: what do we need to know?
Journal of thrombosis and thrombolysis 2010;29(2):199-207.
2010: Jeffrey I Weitz
New oral anticoagulants in development.
Thrombosis and haemostasis 2010;103(1):62-70.
2010: Colin A Kretz; Karl K Cuddy; Alan R Stafford; James C Fredenburgh; Robin Roberts; Jeffrey I Weitz
HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions.
Thrombosis and haemostasis 2010;103(1):83-93.
2009: Nicolas S Petrera; Alan R Stafford; Beverly A Leslie; Colin A Kretz; James C Fredenburgh; Jeffrey I Weitz
Long range communication between exosites 1 and 2 modulates thrombin function.
The Journal of biological chemistry 2009;284(38):25620-9.
2009: P L Gross; Jeffrey I Weitz
New antithrombotic drugs.
Clinical pharmacology and therapeutics 2009;86(2):139-46.
2009: Jeffrey I Weitz
Prevention and treatment of venous thromboembolism during pregnancy.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2009;74 Suppl 1():S22-6.
2009: Ji Zhou; Linda May; Peng Liao; Peter L Gross; Jeffrey I Weitz
Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(6):863-9.
2009: Jeffrey I Weitz
Unanswered questions in venous thromboembolism.
Thrombosis research 2009;123 Suppl 4():S2-S10.
2008: Samira B Jeimy; Nola Fuller; Subia Tasneem; Kenneth Segers; Alan R Stafford; Jeffrey I Weitz; Rodney M Camire; Gerry A F Nicolaes; Catherine P M Hayward
Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation.
Thrombosis and haemostasis 2008;100(6):1058-67.
2008: Clive Kearon; Jim A Julian; Michael J Kovacs; David R Anderson; Philip Wells; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc A Rodger; Julie Hambleton; Michael Gent; Jeffrey S Ginsberg
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.
Blood 2008;112(12):4432-6.
2008: Joanne Yu; Linda May; Chloe Milsom; G Mark Anderson; Jeffrey I Weitz; James P Luyendyk; George Broze; Nigel Mackman; Janusz Rak
Contribution of host-derived tissue factor to tumor neovascularization.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(11):1975-81.
2008: John W Eikelboom; Jeffrey I Weitz
Selective factor Xa inhibition for thromboprophylaxis.
Lancet 2008;372(9632):6-8.
2008: Jeffrey I Weitz; Jack Hirsh; Meyer M Samama
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest 2008;133(6 Suppl):234S-256S.
2008: Peter L Gross; Jeffrey I Weitz
New anticoagulants for treatment of venous thromboembolism.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(3):380-6.
2008: James C Fredenburgh; Alan R Stafford; Beverly A Leslie; Jeffrey I Weitz
Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex.
The Journal of biological chemistry 2008;283(5):2470-7.
2008: Colin K Yee; Martin Butcher; Melec Zeadin; Jeffrey I Weitz; Stephen G Shaughnessy
Inhibition of osteolytic bone metastasis by unfractionated heparin.
Clinical & experimental metastasis 2008;25(8):903-11.
2007: Jeffrey I Weitz
Factor Xa or thrombin: is thrombin a better target?
Journal of thrombosis and haemostasis : JTH 2007;5 Suppl 1():65-7.
2007: Simon J McRae; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
In the presence of phospholipids, glycosaminoglycans potentiate factor Xa-mediated protein C activation by modulating factor Xa activity.
Biochemistry 2007;46(13):4195-203.
2007: Jeffrey I Weitz; Lori-Ann Linkins
Beyond heparin and warfarin: the new generation of anticoagulants.
Expert opinion on investigational drugs 2007;16(3):271-82.
2006: Colin A Kretz; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.
The Journal of biological chemistry 2006;281(49):37477-85.
2006: Jeffrey I Weitz
Emerging anticoagulants for the treatment of venous thromboembolism.
Thrombosis and haemostasis 2006;96(3):274-84.
2006: Lori-Ann Linkins; Jeffrey I Weitz
OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?
Nature clinical practice. Cardiovascular medicine 2006;3(9):478-9.
2006: Raghav Rajgopal; Martin Butcher; Jeffrey I Weitz; Stephen G Shaughnessy
Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway.
The Journal of biological chemistry 2006;281(30):20780-7.
2006: Shannon M Bates; Jeffrey I Weitz
The status of new anticoagulants.
British journal of haematology 2006;134(1):3-19.
2006: Clive Kearon; Jeffrey S Ginsberg; James D Douketis; Alexander G G Turpie; Shannon M Bates; Agnes Y Y Lee; Mark A Crowther; Jeffrey I Weitz; Patrick Brill-Edwards; Philip Wells; David R Anderson; Michael J Kovacs; Lori-Ann Linkins; Jim A Julian; Laura Bonilla; Michael Gent
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial.
Annals of internal medicine 2006;144(11):812-21.
2006: Amy V L Schaefer; Beverly A Leslie; Janice A Rischke; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Biochemistry 2006;45(13):4257-65.
2006: Jeffrey I Weitz
Changing paradigms in the management of venous thromboembolism.
The American heart hospital journal 2006;4(2):135-41.
2005: Jeffrey I Weitz; Shannon M Bates
New anticoagulants.
Journal of thrombosis and haemostasis : JTH 2005;3(8):1843-53.
2005: Shannon M Bates; Jeffrey I Weitz
Coagulation assays.
Circulation 2005;112(4):e53-60.
2005: Shannon M Bates; Jeffrey I Weitz
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.
British journal of pharmacology 2005;144(8):1017-28.
2005: Shamir R Mehta; Philippe Gabriel STEG; Christopher B Granger; Jean-Pierre Bassand; David P Faxon; Jeffrey I Weitz; Rizwan Afzal; Bonnie Rush; Ron J G Peters; Madhu K Natarajan; James L Velianou; David M Goodhart; Marino Labinaz; Jean-Francois Tanguay; Keith A A Fox; Salim Yusuf
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Circulation 2005;111(11):1390-7.
2005: Joanne L Yu; Linda May; Vladimir Lhotak; Siranoush Shahrzad; Senji Shirasawa; Jeffrey I Weitz; Brenda L Coomber; Nigel Mackman; Janusz Rak
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
Blood 2005;105(4):1734-41.
2005: Jack Hirsh; Martin O'Donnell; Jeffrey I Weitz
New anticoagulants.
Blood 2005;105(2):453-63.
2005: Lori-Ann Linkins; Jeffrey I Weitz
Pharmacology and clinical potential of direct thrombin inhibitors.
Current pharmaceutical design 2005;11(30):3877-84.
2005: Michal Vlasin; Janusz Rak; Jeffrey I Weitz; L Peng; J Gumulec; Marilyn Johnston; Petr Klement
Heparin compromises streptokinase-induced arterial patency in rabbits.
Thrombosis research 2005;115(5):427-34.
2005: Lori-Ann Linkins; Jeffrey I Weitz
New anticoagulant therapy.
Annual review of medicine 2005;56():63-77.
2004: James C Fredenburgh; Alan R Stafford; Caroline H Pospisil; Jeffrey I Weitz
Modes and consequences of thrombin's interaction with fibrin.
Biophysical chemistry 2004;112(2-3):277-84.
2004: Patricia C Y Liaw; Charles T Esmon; Kamyar Kahnamoui; Shelley Schmidt; Sarah Kahnamoui; Gary Ferrell; Suzanne Beaudin; Jim A Julian; Jeffrey I Weitz; Mark Crowther; Mark Loeb; Deborah Cook
Patients with severe sepsis vary markedly in their ability to generate activated protein C.
Blood 2004;104(13):3958-64.
2004: Mark Crowther; Jeffrey I Weitz
New anticoagulants: an update.
Clinical advances in hematology & oncology : H&O 2004;2(11):743-9.
2004: Jeffrey I Weitz; Jack Hirsh; Meyer M Samama
New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest 2004;126(3 Suppl):265S-286S.
2004: Jeffrey I Weitz
New anticoagulants for treatment of venous thromboembolism.
Circulation 2004;110(9 Suppl 1):I19-26.
2004: Jeffrey I Weitz
Management of venous thromboembolism: present and future.
Circulation 2004;110(9 Suppl 1):I2.
2004: Edward Young; Vivian Douros; Thomas J Podor; Stephen G Shaughnessy; Jeffrey I Weitz
Localization of heparin and low-molecular-weight heparin in the rat kidney.
Thrombosis and haemostasis 2004;91(5):927-34.
2004: Clive Kearon; Jeffrey S Ginsberg; David R Anderson; Michael J Kovacs; Philip Wells; Jim A Julian; Betsy MacKinnon; Christine Demers; James D Douketis; Alexander G G Turpie; Paul van Nguyen; David Green; Jeannine Kassis; Susan R Kahn; Susan Solymoss; L Desjardins; William Geerts; Marilyn Johnston; Jeffrey I Weitz; Jack Hirsh; Michael Gent
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor.
Journal of thrombosis and haemostasis : JTH 2004;2(5):743-9.
2004: Martin O'Donnell; Jeffrey I Weitz
Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation.
The American journal of managed care 2004;10(3 Suppl):S72-82.
2004: Mark A Crowther; Jeffrey I Weitz
Ximelagatran: the first oral direct thrombin inhibitor.
Expert opinion on investigational drugs 2004;13(4):403-13.
2004: Joanne L Yu; Linda May; Petr Klement; Jeffrey I Weitz; Janusz Rak
Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy.
Seminars in thrombosis and hemostasis 2004;30(1):21-30.
2003: Lori-Ann Linkins; Jeffrey I Weitz
New anticoagulants.
Seminars in thrombosis and hemostasis 2003;29(6):619-31.
2003: Lori-Ann Linkins; Jeffrey I Weitz
An update on new anticoagulants.
Current drug targets. Cardiovascular & haematological disorders 2003;3(4):287-300.
2003: Lee A O'Brien; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Glycosaminoglycans bind factor Xa in a Ca2+-dependent fashion and modulate its catalytic activity.
Biochemistry 2003;42(44):13091-8.
2003: Ericka M Wiebe; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide.
The Journal of biological chemistry 2003;278(37):35767-74.
2003: Shannon M Bates; Jeffrey I Weitz
Emerging anticoagulant drugs.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(9):1491-500.
2003: Clive Kearon; Jeffrey S Ginsberg; Michael J Kovacs; David R Anderson; Philip Wells; Jim A Julian; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc A Rodger; Julie Hambleton; Michael Gent
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
The New England journal of medicine 2003;349(7):631-9.
2003: Jeffrey I Weitz
A novel approach to thrombin inhibition.
Thrombosis research 2003;109 Suppl 1():S17-22.
2003: Caroline H Pospisil; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin.
The Journal of biological chemistry 2003;278(24):21584-91.
2003: Shannon M Bates; Clive Kearon; Mark Crowther; Lori-Ann Linkins; Martin O'Donnell; James D Douketis; Agnes Y Y Lee; Jeffrey I Weitz; Marilyn Johnston; Jeffrey S Ginsberg
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis.
Annals of internal medicine 2003;138(10):787-94.
2003: Martin O'Donnell; Jeffrey I Weitz
Thromboprophylaxis in surgical patients.
Canadian journal of surgery. Journal canadien de chirurgie 2003;46(2):129-35.
2003: Jeffrey I Weitz
Heparan sulfate: antithrombotic or not?
The Journal of clinical investigation 2003;111(7):952-4.
2003: Petr Klement; S Carlsson; Janusz Rak; Peng Liao; Michal Vlasin; Alan R Stafford; Marilyn Johnston; Jeffrey I Weitz
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Journal of thrombosis and haemostasis : JTH 2003;1(3):587-94.
2003: Jeffrey I Weitz; Mark A Crowther
New anticoagulants: current status and future potential.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2003;3(3):201-9.
2003: Jeffrey I Weitz; Eric R Bates
Direct thrombin inhibitors in cardiac disease.
Cardiovascular toxicology 2003;3(1):13-25.
2003: Hayes Dougan; Jeffrey I Weitz; Alan R Stafford; Kris D Gillespie; Petr Klement; John B Hobbs; Donald M Lyster
Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents.
Nuclear medicine and biology 2003;30(1):61-72.
2002: Richard C Austin; Joan E B Fox; Geoff Werstuck; Alan R Stafford; Dennis E Bulman; Ghassan Y Dally; Cameron Ackerley; Jeffrey I Weitz; Peter N Ray
Identification of Dp71 isoforms in the platelet membrane cytoskeleton. Potential role in thrombin-mediated platelet adhesion.
The Journal of biological chemistry 2002;277(49):47106-13.
2002: James C Fredenburgh; Julia A M Anderson; Jeffrey I Weitz
Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin.
Trends in cardiovascular medicine 2002;12(7):281-7.
2002: Lori-Ann Linkins; Jim A Julian; Janice A Rischke; Jack Hirsh; Jeffrey I Weitz
In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
Thrombosis research 2002;107(5):241-4.
2002: Jeffrey I Weitz; Mark Crowther
Direct thrombin inhibitors.
Thrombosis research 2002;106(3):V275-84.
2002: Jeffrey I Weitz; Shannon M Bates
Acute coronary syndromes: a focus on thrombin.
The Journal of invasive cardiology 2002;14 Suppl B():2B-7B.
2002: Thomas J Podor; Stephanie Campbell; Paul Chindemi; Denise M Foulon; David H Farrell; Philip D Walton; Jeffrey I Weitz; Cynthia B Peterson
Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen.
The Journal of biological chemistry 2002;277(9):7520-8.
2002: Thomas J Podor; Davindra Singh; Paul Chindemi; Denise M Foulon; Robert S McKelvie; Jeffrey I Weitz; Richard Austin; Ghislain Boudreau; Richard Davies
Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
The Journal of biological chemistry 2002;277(9):7529-39.
2002: Jeffrey I Weitz; Harry R Buller
Direct thrombin inhibitors in acute coronary syndromes: present and future.
Circulation 2002;105(8):1004-11.
2001: James C Fredenburgh; Alan R Stafford; Jeffrey I Weitz
Conformational changes in thrombin when complexed by serpins.
The Journal of biological chemistry 2001;276(48):44828-34.
2001: Jeffrey I Weitz
New anticoagulant drugs.
Journal of thrombosis and thrombolysis 2001;12(1):7-17.
2001: Clive Kearon; Jeffrey S Ginsberg; James D Douketis; Mark Crowther; Patrick Brill-Edwards; Jeffrey I Weitz; Jack Hirsh
Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing.
Annals of internal medicine 2001;135(2):108-11.
2001: Patricia C Y Liaw; Debra L Becker; Alan R Stafford; James C Fredenburgh; Jeffrey I Weitz
Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin.
The Journal of biological chemistry 2001;276(24):20959-65.
2001: J A Anderson; James C Fredenburgh; Alan R Stafford; Y S Guo; Jack Hirsh; V Ghazarossian; Jeffrey I Weitz
Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase.
The Journal of biological chemistry 2001;276(13):9755-61.
2001: Agnes Y Y Lee; James C Fredenburgh; RJ Stewart; Janice A Rischke; Jeffrey I Weitz
Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Thrombosis and haemostasis 2001;85(3):502-8.
2001: Shannon M Bates; Jeffrey I Weitz; Marilyn Johnston; Jack Hirsh; Jeffrey S Ginsberg
Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.
Archives of internal medicine 2001;161(3):385-91.
2001: John W Eikelboom; Sonia S Anand; Shamir R Mehta; Jeffrey I Weitz; C Yi; Salim Yusuf
Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study.
Circulation 2001;103(5):643-50.
2000: Shannon M Bates; Jeffrey I Weitz
The mechanism of action of thrombin inhibitors.
The Journal of invasive cardiology 2000;12 Suppl F():27F-32.
2000: RJ Stewart; James C Fredenburgh; Janice A Rischke; Laszlo Bajzar; Jeffrey I Weitz
Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator.
The Journal of biological chemistry 2000;275(47):36612-20.
2000: Patrick Brill-Edwards; Jeffrey S Ginsberg; Michael Gent; Jack Hirsh; R Burrows; Clive Kearon; William Geerts; M Kovacs; Jeffrey I Weitz; K Sue Robinson; R Whittom; G Couture
Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group.
The New England journal of medicine 2000;343(20):1439-44.
2000: Thomas J Podor; Cynthia B Peterson; Daniel Lawrence; S Stefansson; Stephen G Shaughnessy; Denise M Foulon; Martin Butcher; Jeffrey I Weitz
Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
The Journal of biological chemistry 2000;275(26):19788-94.
2000: RJ Stewart; James C Fredenburgh; Beverly A Leslie; B A Keyt; Janice A Rischke; Jeffrey I Weitz
Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.
The Journal of biological chemistry 2000;275(14):10112-20.
2000: Hayes Dougan; Donald M Lyster; C V Vo; Alan R Stafford; Jeffrey I Weitz; John B Hobbs
Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood.
Nuclear medicine and biology 2000;27(3):289-97.
2000: Jeffrey I Weitz; Shannon M Bates
Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction.
Archives of internal medicine 2000;160(6):749-58.
1999: Patricia C Y Liaw; Richard C Austin; James C Fredenburgh; Alan R Stafford; Jeffrey I Weitz
Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
The Journal of biological chemistry 1999;274(39):27597-604.
1999: Agnes Y Y Lee; Jim A Julian; Mark N Levine; Jeffrey I Weitz; Clive Kearon; Philip S Wells; Jeffrey S Ginsberg
Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis.
Annals of internal medicine 1999;131(6):417-23.
1999: Jeffrey I Weitz; RJ Stewart; James C Fredenburgh
Mechanism of action of plasminogen activators.
Thrombosis and haemostasis 1999;82(2):974-82.
1999: PA Outinen; Sudesh K Sood; S I Pfeifer; S Pamidi; Thomas J Podor; J Li; Jeffrey I Weitz; Richard C Austin
Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells.
Blood 1999;94(3):959-67.
1999: Debra L Becker; James C Fredenburgh; Alan R Stafford; Jeffrey I Weitz
Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II.
The Journal of biological chemistry 1999;274(10):6226-33.
1999: Stephen G Shaughnessy; Jack Hirsh; Mohit Bhandari; J M Muir; Edward Young; Jeffrey I Weitz
A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats.
Blood 1999;93(4):1231-6.
1999: Jeffrey I Weitz; E Young; Marilyn Johnston; Alan R Stafford; James C Fredenburgh; Jack Hirsh
Vasoflux, a new anticoagulant with a novel mechanism of action.
Circulation 1999;99(5):682-9.
1999: Shannon M Bates; Jeffrey I Weitz
Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin.
Cardiovascular research 1999;41(2):418-32.
1998: Jeffrey S Ginsberg; Philip S Wells; Clive Kearon; D Anderson; Mark Crowther; Jeffrey I Weitz; Janis Bormanis; Patrick Brill-Edwards; Alexander G G Turpie; Betsy MacKinnon; Michael Gent; Jack Hirsh
Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism.
Annals of internal medicine 1998;129(12):1006-11.
1998: Richard C Austin; Sudesh K Sood; A M Dorward; G Singh; Stephen G Shaughnessy; S Pamidi; PA Outinen; Jeffrey I Weitz
Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage.
The Journal of biological chemistry 1998;273(46):30808-17.
1998: Shannon M Bates; Jeffrey I Weitz
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
The American journal of cardiology 1998;82(8B):12P-18P.
1998: Sonia S Anand; Salim Yusuf; Janice Pogue; Jeffrey I Weitz; Marcus Flather
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Circulation 1998;98(11):1064-70.
1998: Mohit Bhandari; Jack Hirsh; Jeffrey I Weitz; Edward Young; Thomas Venner; Stephen G Shaughnessy
The effects of standard and low molecular weight heparin on bone nodule formation in vitro.
Thrombosis and haemostasis 1998;80(3):413-7.
1998: Petr Klement; Peng Liao; Jack Hirsh; Marilyn Johnston; Jeffrey I Weitz
Hirudin causes more bleeding than heparin in a rabbit ear bleeding model.
The Journal of laboratory and clinical medicine 1998;132(3):181-5.
1998: RJ Stewart; James C Fredenburgh; Jeffrey I Weitz
Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
The Journal of biological chemistry 1998;273(29):18292-9.
1998: PA Outinen; Sudesh K Sood; Patricia C Y Liaw; K D Sarge; N Maeda; Jack Hirsh; JC Ribau; Thomas J Podor; Jeffrey I Weitz; Richard C Austin
Characterization of the stress-inducing effects of homocysteine.
The Biochemical journal 1998;332 ( Pt 1)():213-21.
1998: Patricia C Y Liaw; James C Fredenburgh; Alan R Stafford; A Tulinsky; Richard C Austin; Jeffrey I Weitz
Localization of the thrombin-binding domain on prothrombin fragment 2.
The Journal of biological chemistry 1998;273(15):8932-9.
1998: Jeffrey I Weitz; Beverly A Leslie; M Hudoba
Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
Circulation 1998;97(6):544-52.
1998: Shannon M Bates; Jeffrey I Weitz
The new heparins.
Coronary artery disease 1998;9(2-3):65-74.
1997: L Manson; Jeffrey I Weitz; Thomas J Podor; Jack Hirsh; Edward Young
The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance.
The Journal of laboratory and clinical medicine 1997;130(6):649-55.
1997: James C Fredenburgh; Alan R Stafford; Jeffrey I Weitz
Evidence for allosteric linkage between exosites 1 and 2 of thrombin.
The Journal of biological chemistry 1997;272(41):25493-9.
1997: Jeffrey I Weitz
Low-molecular-weight heparins.
The New England journal of medicine 1997;337(10):688-98.
1997: Hayes Dougan; John B Hobbs; Jeffrey I Weitz; Donald M Lyster
Synthesis and radioiodination of a stannyl oligodeoxyribonucleotide.
Nucleic acids research 1997;25(14):2897-901.
1997: Jeffrey S Ginsberg; Clive Kearon; James D Douketis; Alexander G G Turpie; Patrick Brill-Edwards; P Stevens; Akbar Panju; A Patel; Mark Crowther; Maureen Andrew; Patricia Massicotte; Jack Hirsh; Jeffrey I Weitz
The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis.
Archives of internal medicine 1997;157(10):1077-81.
1997: J M Muir; Jack Hirsh; Jeffrey I Weitz; Maureen Andrew; Edward Young; Stephen G Shaughnessy
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.
Blood 1997;89(9):3236-42.
1997: B Cosmi; James C Fredenburgh; Janice A Rischke; Jack Hirsh; E Young; Jeffrey I Weitz
Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Circulation 1997;95(1):118-24.
1997: Debra L Becker; James C Fredenburgh; Alan R Stafford; Jeffrey I Weitz
Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes.
Advances in experimental medicine and biology 1997;425():55-66.
1996: J M Muir; Maureen Andrew; J Hirsh; Jeffrey I Weitz; Edward Young; P Deschamps; Stephen G Shaughnessy
Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.
Blood 1996;88(4):1314-20.
1996: Jeffrey I Weitz
Biological rationale for the therapeutic role of specific antithrombins.
Coronary artery disease 1996;7(6):409-19.
1996: Petr Klement; J M Augustine; K H Delaney; G Klement; Jeffrey I Weitz
An oral ivermectin regimen that eradicates pinworms (Syphacia spp.) in laboratory rats and mice.
Laboratory animal science 1996;46(3):286-90.
1996: J S Ginsberg; S Siragusa; James D Douketis; Marilyn Johnston; K Moffat; D Donovan; Joanne A McGinnis; Patrick Brill-Edwards; Akbar Panju; A Patel; Jeffrey I Weitz
Evaluation of a soluble fibrin assay in patients with suspected pulmonary embolism.
Thrombosis and haemostasis 1996;75(4):551-4.
1996: Jeffrey I Weitz
Elevated fibrinopeptide A and B levels during thrombolytic therapy: real or artefactual?
Thrombosis and haemostasis 1996;75(4):529-35.
1996: Kimberly A Woodhouse; Jeffrey I Weitz; John L Brash
Lysis of surface-localized fibrin clots by adsorbed plasminogen in the presence of tissue plasminogen activator.
Biomaterials 1996;17(1):75-7.
1995: Jeffrey I Weitz
Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
Journal of vascular and interventional radiology : JVIR 1995;6(6 Pt 2 Suppl):19S-23S.
1995: MT Leaker; LA Brooker; L G Mitchell; Jeffrey I Weitz; R Superina; M E Andrew
Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
Transplantation 1995;60(2):144-7.
1995: Alexander G G Turpie; Jeffrey I Weitz; J Hirsh
Advances in antithrombotic therapy: novel agents.
Thrombosis and haemostasis 1995;74(1):565-71.
1995: Philip S Wells; Patrick Brill-Edwards; P Stevens; Akbar Panju; A Patel; James D Douketis; M Patricia Massicotte; J Hirsh; Jeffrey I Weitz; Clive Kearon
A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis.
Circulation 1995;91(8):2184-7.
1994: Kimberly A Woodhouse; Jeffrey I Weitz; John L Brash
Interactions of plasminogen and fibrinogen with model silica glass surfaces: adsorption from plasma and enzymatic activity studies.
Journal of biomedical materials research 1994;28(4):407-15.
1993: Jeffrey I Weitz; B Leslie; J Hirsh; Petr Klement
Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
The Journal of clinical investigation 1993;91(4):1343-50.
1993: Fraser D Rubens; Jeffrey I Weitz; John L Brash; Raelene L Kinlough-Rathbone
The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Thrombosis and haemostasis 1993;69(2):130-4.
1993: D R Anderson; Anthonie W A Lensing; Philip S Wells; M N Levine; Jeffrey I Weitz; J Hirsh
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis.
Annals of internal medicine 1993;118(1):25-30.
1992: John D Loike; R Silverstein; Samuel D Wright; Jeffrey I Weitz; A J Huang; Samuel C. Silverstein
The role of protected extracellular compartments in interactions between leukocytes, and platelets, and fibrin/fibrinogen matrices.
Annals of the New York Academy of Sciences 1992;667():163-72.
1992: C Demers; J S Ginsberg; P Henderson; Frederick A Ofosu; Jeffrey I Weitz; Morris A Blajchman
Measurement of markers of activated coagulation in antithrombin III deficient subjects.
Thrombosis and haemostasis 1992;67(5):542-4.
1992: Jeffrey I Weitz; E K Silverman; B Thong; E J Campbell
Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor.
The Journal of clinical investigation 1992;89(3):766-73.
1992: Jeffrey I Weitz; J Hirsh
Antithrombins: their potential as antithrombotic agents.
Annual review of medicine 1992;43():9-16.
1991: Jeffrey I Weitz; J Kuint; B Leslie; J Hirsh
Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis or fibrinogenolysis.
Thrombosis and haemostasis 1991;65(5):541-4.
1991: Jeffrey I Weitz; B Leslie; J Ginsberg
Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
The Journal of clinical investigation 1991;87(3):1082-90.
1991: John D Loike; Beate Sodeik; Long Cao; S Leucona; Jeffrey I Weitz; P A Detmers; Samuel D Wright; Samuel C. Silverstein
CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(3):1044-8.
1991: Jeffrey I Weitz
Development and application of assays for elastase-specific fibrinogen fragments.
Annals of the New York Academy of Sciences 1991;624():154-66.
1990: Jeffrey I Weitz; M Hudoba; D Massel; J Maraganore; J Hirsh
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
The Journal of clinical investigation 1990;86(2):385-91.
1990: Jeffrey I Weitz; B Leslie
Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.
The Journal of clinical investigation 1990;86(1):203-12.
1988: Jeffrey I Weitz; M K Cruickshank; B Thong; B Leslie; Mark N Levine; J Ginsberg; T Eckhardt
Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.
The Journal of clinical investigation 1988;82(5):1700-7.
1988: Samuel D Wright; Jeffrey I Weitz; A J Huang; S M Levin; Samuel C. Silverstein; John D Loike
Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(20):7734-8.
1987: Jeffrey I Weitz; A J Huang; S L Landman; S C Nicholson; Samuel C. Silverstein
Elastase-mediated fibrinogenolysis by chemoattractant-stimulated neutrophils occurs in the presence of physiologic concentrations of antiproteinases.
The Journal of experimental medicine 1987;166(6):1836-50.
1987: J Levy; Michael Pettei; Jeffrey I Weitz
Dysfibrinogenemia in obstructive liver disease.
Journal of pediatric gastroenterology and nutrition 1987;6(6):967-70.
1987: Jeffrey I Weitz; K A Crowley; S L Landman; B I Lipman; J Yu
Increased neutrophil elastase activity in cigarette smokers.
Annals of internal medicine 1987;107(5):680-2.
1986: Jeffrey I Weitz; S L Landman; K A Crowley; S Birken; F J Morgan
Development of an assay for in vivo human neutrophil elastase activity. Increased elastase activity in patients with alpha 1-proteinase inhibitor deficiency.
The Journal of clinical investigation 1986;78(1):155-62.
1986: Jeffrey I Weitz; J A Koehn; Robert E Canfield; S L Landman; R Friedman
Development of a radioimmunoassay for the fibrinogen-derived peptide B beta 1-42.
Blood 1986;67(4):1014-22.